Asia Hep B Trials Could Preview U.S. Studies - Analyst
This article was originally published in PharmAsia News
Executive Summary
As clinical development programs mature in Asia, U.S. investors and analysts may increasingly look to Asian clinical trials to get a preview of a compound's potential success in U.S. markets